(Q37686830)

22 August 2017

1 reference

title

Long-term cervical cancer prevention strategies across the globe (English)

1 reference

22 August 2017

main subject

cervix uterine cancer

1 reference

Jack Cuzick

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

2 February 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

117

1 reference

22 August 2017

issue

2 Suppl

1 reference

22 August 2017

page(s)

S11-4

1 reference

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Cervical cancer screening following prophylactic human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Description of the national situation of cervical cancer screening in the member states of the European Union

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Evaluation of alternative methods of cervical cancer screening for resource-poor settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.01.025

10.1016/J.YGYNO.2010.01.025

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference